Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Abstract Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with oestrogen-receptor-positive (ER+), HER2-negative breast cancer. Here,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Richard Buus, Zsolt Szijgyarto, Eugene F. Schuster, Hui Xiao, Ben P. Haynes, Ivana Sestak, Jack Cuzick, Laia Paré, Elia Seguí, Nuria Chic, Aleix Prat, Mitch Dowsett, Maggie Chon U. Cheang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/ab6604a1505e46ae8d5a30ae6561a42c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares